Azacitidine C₈H₁₂N₄O₅
Also known as: Azacytidine

Therapeutic indications

Azacitidine is indicated for:

Myelodysplastic syndromes, chronic myelomonocytic leukaemia, acute myeloid leukaemia

Population group: both men and women, only adults (18 years old or older)

Azacitidine is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:

  • intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
  • chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder,
  • acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,
  • AML with >30% marrow blasts according to the WHO classification.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Azacitidine is contraindicated in the following cases:

Lactation

Lactation

Advanced malignant hepatic tumours

Malignant neoplasm of liver (disorder)

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: VIDAZA Powder for suspension for injection
Summary of Product Characteristics (SPC) 2021: ONUREG Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈